Latest Vagus nerve stimulation Stories

Cyberonics Announces Response To Submission For Reconsideration Of Coverage Of VNS Therapy® in Treatment-Resistant Depression

2013-05-28 20:21:49

HOUSTON, May 28, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced the receipt of a letter from the Centers of Medicare and Medicaid Services (CMS) declining the company's request to reconsider the 2007 National Coverage Determination for the treatment-resistant depression indication. "Cyberonics is very disappointed in the position taken by CMS that the new evidence accumulated over the past five years and recently published in four peer-reviewed journals does...

Cyberonics To Report Fourth Quarter And Fiscal Year 2013 Results And Host Webcast And Conference Call On June 5, 2013

2013-05-07 08:32:39

HOUSTON, May 7, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the fourth quarter and fiscal year ended April 26, 2013, on Wednesday, June 5, 2013, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time). Fourth Quarter and Fiscal Year 2013 Results Webcast and Conference Call InstructionsThe conference...

North America Leads Neuromodulation Market Says Research Report - New Report by MarketsandMarkets

2013-04-28 23:02:09

[193 Pages Report] Neuromodulation market report categorizes the global market on the basis of (Spinal Cord, Vagus Nerve, Deep Brain, Sacral Nerve & Transcranial Magnetic) Stimulation by procedure, technology and application forecasting 2012 - 2017. (PRWEB) April 28, 2013 Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS) & Transcranial Magnetic...

Frost & Sullivan: More than 10 Million U.S. Patients Treatable by Neurostimulation, Driving Uptake

2013-04-24 08:29:10

Cost-effective, user-friendly solutions with successful clinical outcomes fuel adoption MOUNTAIN VIEW, Calif., April 24, 2013 /PRNewswire/ -- The neurostimulation device market in the United States is poised for rapid growth as increasing patient dissatisfaction with conventional therapies spurs demand for alternative, less-invasive treatment solutions. The country's growing number of aging people and the high incidence of neurological disorders and chronic conditions leads...

Cyberonics Provides Update On Submission To CMS

2013-04-04 08:29:36

HOUSTON, April 4, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today provided an update on its recent submission to the Centers for Medicare & Medicaid Services ("CMS") seeking reimbursement coverage for the treatment-resistant depression ("TRD") indication for the VNS Therapy(®) System. As previously announced, the company submitted a request to CMS for reconsideration of coverage for VNS Therapy for TRD and expected to receive a formal acknowledgment from CMS accepting...

Research and Markets Announces The Release of 'Neuromodulation Market - Forecasts to 2017'

2013-03-25 12:27:11

DUBLIN, March 25, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/t8zp6f/neuromodulation) has announced the addition of the "Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017" report to their offering. (Logo:...

Global Neurostimulation Market 2013 Report

2013-02-22 23:01:23

Research and Markets announces the addition of "Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017" to its catalogue. (PRWEB) February 22, 2013 Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for...

ElectroCore® Receives Australian and Colombian Regulatory Approval for GammaCore® Vagal Nerve Stimulation Therapy

2013-02-19 08:34:05

MORRIS PLAINS, N.J., Feb. 19, 2013 /PRNewswire/ -- ElectroCore(®), a company dedicated to developing effective, non-invasive Vagal Nerve Stimulation (nVNS) therapies for serious medical conditions including primary headaches, announced today that its GammaCore(®) therapy has been approved for commercial sale by the Therapeutic Goods Administration in Australia and the National Institute of Surveillance of Medicine and Foods in the Ministry of Health in Colombia. GammaCore's...

Cyberonics to Participate in Upcoming Investor Conferences

2013-02-13 08:28:47

HOUSTON, Feb. 13, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the following conferences. Dan Moore, Cyberonics' President & Chief Executive Officer, will participate in the neuromodulation panel discussion at the Citi 2013 Global Healthcare Conference in New York on Wednesday, February 27, 2013 at 11:05 AM Eastern Time. This panel discussion will not...

Cyberonics to Report Fiscal Year 2013 Third Quarter Results and Host Webcast and Conference Call on February 22, 2013

2013-02-06 08:27:16

HOUSTON, Texas, Feb. 6, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that the company will report financial results for the third quarter ended January 25, 2013, of its fiscal year ending April 26, 2013, on Friday, February 22, 2013, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time). Fiscal Year 2013 Third Quarter Results Webcast and...